Short Interest in Gossamer Bio, Inc. (NASDAQ:GOSS) Declines By 12.8%

Gossamer Bio, Inc. (NASDAQ:GOSS) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 6,120,000 shares, a drop of 12.8% from the December 15th total of 7,020,000 shares. Based on an average daily volume of 1,330,000 shares, the days-to-cover ratio is currently 4.6 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $9.20.

Institutional Trading of Gossamer Bio

Institutional investors and hedge funds have recently modified their holdings of the stock. US Bancorp DE bought a new stake in Gossamer Bio during the third quarter worth $39,000. Choreo LLC purchased a new position in Gossamer Bio during the 2nd quarter worth $46,000. GSA Capital Partners LLP bought a new stake in shares of Gossamer Bio in the 3rd quarter worth $67,000. Algert Global LLC purchased a new stake in shares of Gossamer Bio in the second quarter valued at about $75,000. Finally, Sequoia Financial Advisors LLC lifted its position in shares of Gossamer Bio by 26.7% during the third quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock valued at $117,000 after purchasing an additional 25,000 shares in the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Stock Down 3.8 %

GOSS stock traded down $0.04 during midday trading on Friday, reaching $0.96. 817,985 shares of the company’s stock traded hands, compared to its average volume of 1,082,774. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm’s fifty day moving average price is $0.84 and its 200-day moving average price is $0.91. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.60. The company has a market cap of $217.97 million, a price-to-earnings ratio of -3.01 and a beta of 1.81.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. The business had revenue of $9.48 million for the quarter, compared to the consensus estimate of $4.52 million. As a group, sell-side analysts forecast that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.